MSC11FCD

DRUG2 trials

Sponsors

CHA University

Conditions

Adult GliosarcomaGlioblastomaGlioblastoma (GBM)Neoplasms, BrainNeoplasms, Germ Cell and EmbryonalNewly Diagnosed Glioblastoma MultiformeRecurrent Glioblastoma

Phase 1

Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

CompletedNCT04657315

CHA UniversityAdult Gliosarcoma, Glioblastoma, Neoplasms, Brain +2

Start: 2020-06-24End: 2022-12-22Updated: 2023-01-18

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

RecruitingNCT07143812

CHA UniversityGlioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme

Start: 2025-10-23End: 2026-12-31Target: 10Updated: 2026-01-22

Related Papers

Suicide gene therapy for recurrent glioblastoma using allogeneic bone marrow–derived mesenchymal stem cell gene delivery (MSC/CD): A first-in-human, dose-escalation phase I clinical trial.

Journal of Clinical Oncology2026-05-27